Loading...
Loading...
JAN| Name | Value |
|---|---|
| Revenues | 10.5M |
| Cost of Revenue | 8.9M |
| Gross Profit | 1.6M |
| Operating Expense | 2.9M |
| Operating I/L | -1.3M |
| Other Income/Expense | 11.9M |
| Interest Income | 0.0M |
| Pretax | 10.7M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 10.7M |
JanOne Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing non-opioid and non-addictive therapies for pain and addiction. The company operates through three segments: Biotechnology, Recycling, and Technology. Its lead product candidate, JAN101, is an oral pharmaceutical composition targeting poor blood flow in patients with diabetes or peripheral artery disease to treat pain. Additionally, the company provides appliance recycling and replacement services for energy efficiency programs, as well as designs and sells cellular transceiver modules and wireless services.
